<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492726</url>
  </required_header>
  <id_info>
    <org_study_id>11976</org_study_id>
    <secondary_id>2006-000874-56</secondary_id>
    <nct_id>NCT00492726</nct_id>
  </id_info>
  <brief_title>Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem</brief_title>
  <official_title>A Prospective, Randomized, Double-dummy, Double-blind, Multicenter Trial Comparing the Safety and Efficacy of Intravenous Moxifloxacin 400 mg IV QD 24 Hours to That of Ertapenem 1.0 g IV QD 24 Hours for 5 to 14 Days for the Treatment of Subjects With Complicated Intra-abdominal Infections (PROMISE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to compare the safety and efficacy of moxifloxacin to ertapenem in patients with
      intra-abdominal infections.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population</measure>
    <time_frame>21 to 28 days after completion of study drug therapy</time_frame>
    <description>Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Clinical Improvement During Treatment in the Per Protocol Population</measure>
    <time_frame>During treatment at day 5 +/- 1 day</time_frame>
    <description>Clinical improvement = Reduction in the severity and/or number of signs and symptoms of infection.Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Bacteriological Success During Treatment in the Per Protocol Population With Causative Organism(s)</measure>
    <time_frame>During treatment at day 5 +/- 1 day</time_frame>
    <description>Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Clinical Cure at End of Therapy (EOT) Visit in the Per Protocol Population</measure>
    <time_frame>after 5 - 14 days of therapy</time_frame>
    <description>Clinical cure = resolution/improvement of clinical signs and symptoms related to the infection without wound infection requiring systemic antibiotic treatment. Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Bacteriological Success at EOT Visit in the Per Protocol Population With Causative Organism(s)</measure>
    <time_frame>After 5 - 14 days of therapy</time_frame>
    <description>Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Bacteriological Success at TOC Visit in the Per Protocol Population With Causative Organism(s)</measure>
    <time_frame>21 - 28 days after end of therapy</time_frame>
    <description>Bacteriological success = response classified as 'eradication' or 'presumed eradication' without occurrence of a superinfection. Bacteriological failure = response classified as 'persistence', 'presumed persistence', or 'superinfection' - additionally, any recurrence or reinfection was treated as bacteriological failure at TOC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving Clinical Cure at TOC Visit in the Per Protocol Population With Causative Organism(s)</measure>
    <time_frame>21 - 28 days after end of therapy</time_frame>
    <description>Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Died Due to Intra-abdominal Infections</measure>
    <time_frame>21 - 28 days after end of treatment at TOC Visit</time_frame>
    <description>Number of subjects who had died due to intra abdominal infections by the time of TOC visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>From the first admission date to the discharge date (from 4 to 71 days after start of study medication)</time_frame>
    <description>Duration of hospitalization in the per protocol population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization Postoperatively</measure>
    <time_frame>Duration of hospitalization after the first surgery until discharge date (from 4 to 71 days after start of study medication)</time_frame>
    <description>Duration of hospitalization after the first surgery until discharge in the per protocol population.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">804</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Moxifloxacin (Avelox, BAY12-8039)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertapenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin (Avelox, BAY12-8039)</intervention_name>
    <description>Moxifloxacin, 400mg, administered intravenously once daily</description>
    <arm_group_label>Moxifloxacin (Avelox, BAY12-8039)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertapenem intravenous</intervention_name>
    <description>Active treatment: Ertapenem 1.0g, administered intravenously once daily</description>
    <arm_group_label>Ertapenem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized men or women &gt;/=18 years of age

          -  Expected duration of treatment with intravenous antibiotics anticipated to be &gt;/= 5
             full days but not exceeding 14 days

          -  Ability to provide documented and signed written informed consent

          -  Confirmed or suspected intra abdominal infection defined as follows:

               -  For a confirmed intra abdominal infection, a surgical procedure (laparotomy or
                  laparoscopy) must have been performed within 24 hours prior to enrollment and
                  reveal at least one of the following:

                    -  Gross peritoneal inflammation with purulent exudates (i.e. peritonitis)

                    -  Intra abdominal abscess

                    -  Macroscopic intestinal perforation with localized or diffuse peritonitis

          -  Subjects enrolled on the basis of a suspected intra abdominal infection must have:

               -  Radiological evidence [abdominal plain films, computed tomography (CT), magnetic
                  resonance imaging (MRI) or ultrasound] of gastrointestinal perforation or
                  intra-abdominal abscess and the following signs and symptoms:

                    -  Symptoms referable to the abdominal cavity (e.g. anorexia, nausea, vomiting
                       or pain), lasting for at least 24 hours

                    -  Tenderness (with or without rebound), involuntary guarding, absent or
                       diminished bowel sounds, or abdominal wall rigidity

               -  At least two of the following SIRS criteria:

                    -  Temperature &gt; 38.0°C rectal or tympanic membrane, or temperature &lt; 36.0°C
                       rectal or tympanic

                    -  Heart rate &gt; 90/min

                    -  Respiratory rate &gt; 20/min

                    -  WBC &gt;12,000 cells/mm3 or &lt; 4,000 cells/ mm3

               -  The subject must be scheduled for a surgical procedure (laparotomy or
                  laparoscopy) within 24 hours of enrollment of the study

        Exclusion Criteria:

          -  Known hypersensitivity to quinolones, and/or to carbapenems and/or to any other type
             of beta lactam antibiotic drugs (e.g. penicillins or cephalosporins), or any of the
             excipients

          -  Women who are pregnant or lactating or in whom pregnancy cannot be excluded

          -  History of tendon disease/disorder related to quinolone treatment

          -  Known congenital or documented acquired QT prolongation; uncorrected hypokalemia;
             clinically relevant bradycardia; clinically relevant heart failure with reduced left
             ventricular ejection fraction; previous history of symptomatic arrhythmias

          -  Concomitant use of any of the following drugs, reported to increase the QT interval:
             antiarrhythmics class IA (e.g. quinidine, hydroquinidine, disopyramide) or
             antiarrhythmics class III (e.g., amiodarone, sotalol, dofetilide, ibutilide),
             neuroleptics (e.g. phenothiazines, pimozide, sertindole, haloperidol, sultopride),
             tricyclic antidepressive agents, certain antimicrobials (sparfloxacin, erythromycin
             IV, pentamidine, antimalarials, particularly halofantrine), certain antihistaminics
             (terfenadine, astemizole, mizolastine), and others (cisapride, vincamine IV, bepridil,
             diphemanil)

          -  Known severe end stage liver disease

          -  Creatinine clearance &lt;/= 30 mL/min/1.73 m2

          -  Systemic antibacterial therapy administered for more than 24 hours within 7 days of
             enrollment

          -  Need for systemic antibacterial therapy with agents other than those described in the
             study protocol

          -  Indwelling peritoneal catheter

          -  Pre existing ascites and presumed spontaneous bacterial peritonitis

          -  Perforation of the stomach or duodenum, if the duration of perforation is less than 24
             hours or if operated on within 24 hours of perforation

          -  Perforation of the small bowel (excluding the duodenum) or large bowel, if the
             duration of perforation is less than 12 hours or if operated on within 12 hours of
             perforation

          -  All pancreatic processes including pancreatic sepsis, peri-pancreatic sepsis, or an
             intra abdominal infection secondary to pancreatitis

          -  Liver and splenic abscess

          -  Transmural bowel ischemia or necrosis without perforation or established peritonitis
             or abscess

          -  Acute and gangrenous cholecystitis without perforation

          -  Acute cholangitis

          -  Early acute, suppurative, or gangrenous non-perforated appendicitis

          -  Subjects requiring antibiotic irrigations of the abdominal cavity or surgical wound

          -  Treatment with &quot;open abdomen&quot; or marsupialization, or multiple planned re laparotomies

          -  Infections originating from the female genital tract

          -  Peri-nephric infections

          -  Evidence of sepsis with shock requiring the administration of vasopressors for more
             than 4 consecutive hours

          -  Known rapidly fatal underlying disease (death expected within 6 months)

          -  Neutropenia (neutrophil count &lt; 1,000/mL) caused by immunosuppressive therapy or
             malignancy

          -  Receiving chronic treatment with known immunosuppressant therapy (including chronic
             treatment with &gt; 15 mg/day of systemic prednisone or equivalent)

          -  Subjects known to have AIDS (CD4 count &lt; 200/mL) or HIV seropositives who are
             receiving HAART (HIV positive subjects may be included. HIV testing is not required
             for this study protocol)

          -  Subjects with a malignant or pre malignant hematological condition, including
             Hodgkin's disease and non-Hodgkin lymphoma (subjects with solid tumor can be included
             in the study)

          -  Subjects with a Body Mass Index &gt;/= 45 kg/m2

          -  Previous enrollment in this study

          -  Participation in any clinical investigational drug study within the previous 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Ciudadela</city>
        <state>Buenos Aires</state>
        <zip>B1702FWM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>de Febrero 3</city>
        <state>Buenos Aires</state>
        <zip>1657</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florencio Varela</city>
        <state>Buenos Aires</state>
        <zip>1888</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merlo</city>
        <state>Buenos Aires</state>
        <zip>B1712FJN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Auton. de Buenos Aires</state>
        <zip>C1180AAX</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Córdoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruxelles - Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rousse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kohtla-Jarve</city>
        <zip>30322</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallin</city>
        <zip>EE-13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tartu</city>
        <zip>EE-51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amilly Cedex</city>
        <zip>45207</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beeskow</city>
        <state>Brandenburg</state>
        <zip>15848</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paderborn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio Patras</city>
        <zip>265 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liepaja</city>
        <zip>3402</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rezekne</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <zip>LV-1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valmiera</city>
        <zip>LV-4201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <zip>45130</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <zip>10207</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <zip>LT-04130</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <zip>300748</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>115280</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>119048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu</url>
    <description>Click here and search for information of Bayer products for Europe</description>
  </link>
  <results_reference>
    <citation>De Waele JJ, Tellado JM, Alder J, Reimnitz P, Jensen M, Hampel B, Arvis P. Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study. Int J Antimicrob Agents. 2013 Jan;41(1):57-64. doi: 10.1016/j.ijantimicag.2012.08.013. Epub 2012 Nov 13.</citation>
    <PMID>23153963</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2007</study_first_submitted>
  <study_first_submitted_qc>June 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <results_first_submitted>February 11, 2010</results_first_submitted>
  <results_first_submitted_qc>February 11, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2010</results_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Complicated Intra-Abdominal Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Ertapenem</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 02 July 2006 to 31 December 2008 at 52 centers in 14 countries: Argentina (9), Belgium (3), Bulgaria (4), Estonia (3), France (2 ), Germany (5), Greece (1), Israel (2), Latvia (6), Lithuania (4), Romania (5), Russia (3), South Africa (3), and Spain (2).</recruitment_details>
      <pre_assignment_details>830 subjects screened, 804 randomized. 6 not treated. Safety/Intent to treat population = 798 subjects with at least 1 dose taken and 1 observation after intake (Moxifloxacin 408; Ertapenem 390). Per protocol population = 699 subjects with no major protocol deviations that would have influenced the primary outcome (Moxifloxacin 352; Ertapenem 347).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Moxifloxacin (Avelox, BAY12-8039)</title>
          <description>Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.</description>
        </group>
        <group group_id="P2">
          <title>Ertapenem</title>
          <description>Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="410"/>
                <participants group_id="P2" count="394"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>End of Treatment (EOT, Day 5 to 14)</title>
              <participants_list>
                <participants group_id="P1" count="387"/>
                <participants group_id="P2" count="377"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>End of Study</title>
              <participants_list>
                <participants group_id="P1" count="360"/>
                <participants group_id="P2" count="358"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="360"/>
                <participants group_id="P2" count="358"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliant with study medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Moxifloxacin (Avelox, BAY12-8039)</title>
          <description>Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.</description>
        </group>
        <group group_id="B2">
          <title>Ertapenem</title>
          <description>Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="410"/>
            <count group_id="B2" value="394"/>
            <count group_id="B3" value="804"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.1" spread="18.3"/>
                    <measurement group_id="B2" value="47.0" spread="18.2"/>
                    <measurement group_id="B3" value="47.4" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population</title>
        <description>Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC.</description>
        <time_frame>21 to 28 days after completion of study drug therapy</time_frame>
        <population>The per protocol population was the main analysis set for the assessment of clinical response and was defined as those subjects with no major protocol deviations that would have influenced the primary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin (Avelox, BAY12-8039)</title>
            <description>Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ertapenem</title>
            <description>Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol Population</title>
          <description>Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC.</description>
          <population>The per protocol population was the main analysis set for the assessment of clinical response and was defined as those subjects with no major protocol deviations that would have influenced the primary outcome.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315"/>
                    <measurement group_id="O2" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Calculated were 95% confidence intervals for the difference in success rates between treatment groups (moxifloxacin minus comparator).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin was set to 10% in the protocol, in agreement with FDA recommendations. Sample size was estimated using the method as described in Farrington-Manning. Estimation was performed to achieve 85% power, based on the equivalence delta of 10%, and a clinical success rate of 80% in the per protocol population.</non_inferiority_desc>
            <param_type>Difference of cure rates (in percent)</param_type>
            <param_value>-3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.9</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>A positive value indicates an advantage for the treatment group of moxifloxacin, a negative value an advantage for the comparator group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Clinical Improvement During Treatment in the Per Protocol Population</title>
        <description>Clinical improvement = Reduction in the severity and/or number of signs and symptoms of infection.Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered.</description>
        <time_frame>During treatment at day 5 +/- 1 day</time_frame>
        <population>Per protocol population comprising subjects with no major protocol deviations that would have influenced the primary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin (Avelox, BAY12-8039)</title>
            <description>Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ertapenem</title>
            <description>Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Clinical Improvement During Treatment in the Per Protocol Population</title>
          <description>Clinical improvement = Reduction in the severity and/or number of signs and symptoms of infection.Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered.</description>
          <population>Per protocol population comprising subjects with no major protocol deviations that would have influenced the primary outcome.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Calculated were 95% confidence intervals for the difference in success rates between treatment groups (moxifloxacin minus comparator).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size estimation was based on the primary efficacy variable.</non_inferiority_desc>
            <param_type>Difference in improvement rates (in %)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
            <estimate_desc>A positive value indicates an advantage for the treatment group of moxifloxacin, a negative value an advantage for the comparator group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Bacteriological Success During Treatment in the Per Protocol Population With Causative Organism(s)</title>
        <description>Bacteriological success = response classified as ‘eradication’ or ‘presumed eradication’ without occurrence of a superinfection. Bacteriological failure = response classified as ‘persistence’, ‘presumed persistence’, or ‘superinfection’.</description>
        <time_frame>During treatment at day 5 +/- 1 day</time_frame>
        <population>Per protocol population (subjects with no major protocol deviations that would have influenced the primary outcome) with causative organism(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin (Avelox, BAY12-8039)</title>
            <description>Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ertapenem</title>
            <description>Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Bacteriological Success During Treatment in the Per Protocol Population With Causative Organism(s)</title>
          <description>Bacteriological success = response classified as ‘eradication’ or ‘presumed eradication’ without occurrence of a superinfection. Bacteriological failure = response classified as ‘persistence’, ‘presumed persistence’, or ‘superinfection’.</description>
          <population>Per protocol population (subjects with no major protocol deviations that would have influenced the primary outcome) with causative organism(s).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Eradication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presumed Eradication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presumed Persistence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Superinfections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Calculated were 95% confidence intervals for the difference in success rates between treatment groups (moxifloxacin minus comparator).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size estimation was based on the primary efficacy variable.</non_inferiority_desc>
            <param_type>Difference in bact. success rates (in %)</param_type>
            <param_value>-3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.8</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>A positive value indicates an advantage for the treatment group of moxifloxacin, a negative value an advantage for the comparator group. Presumed eradications and eradications without superinfection were considered bacteriological successes.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Clinical Cure at End of Therapy (EOT) Visit in the Per Protocol Population</title>
        <description>Clinical cure = resolution/improvement of clinical signs and symptoms related to the infection without wound infection requiring systemic antibiotic treatment. Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered.</description>
        <time_frame>after 5 - 14 days of therapy</time_frame>
        <population>Per protocol population comprising subjects with no major protocol deviations that would have influenced the primary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin (Avelox, BAY12-8039)</title>
            <description>Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ertapenem</title>
            <description>Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Clinical Cure at End of Therapy (EOT) Visit in the Per Protocol Population</title>
          <description>Clinical cure = resolution/improvement of clinical signs and symptoms related to the infection without wound infection requiring systemic antibiotic treatment. Clinical failure = Failure to respond/insufficient lessening of signs and symptoms of infection requiring a modification/addition of antibacterial therapy, or a second surgical intervention (unless the original surgery was deemed inadequate). Development of a wound infection requiring alternative/additional antibiotic therapy was considered a failure. Failed subjects must have had 3 full days of therapy administered.</description>
          <population>Per protocol population comprising subjects with no major protocol deviations that would have influenced the primary outcome.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328"/>
                    <measurement group_id="O2" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Calculated were 95% confidence intervals for the difference in success rates between treatment groups (moxifloxacin minus comparator).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size estimation was based on the primary efficacy variable.</non_inferiority_desc>
            <param_type>Difference of cure rates (in percent)</param_type>
            <param_value>-1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
            <estimate_desc>A positive value indicates an advantage for the treatment group of moxifloxacin, a negative value an advantage for the comparator group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Bacteriological Success at EOT Visit in the Per Protocol Population With Causative Organism(s)</title>
        <description>Bacteriological success = response classified as ‘eradication’ or ‘presumed eradication’ without occurrence of a superinfection. Bacteriological failure = response classified as ‘persistence’, ‘presumed persistence’, or ‘superinfection’.</description>
        <time_frame>After 5 - 14 days of therapy</time_frame>
        <population>Per protocol population (subjects with no major protocol deviations that would have influenced the primary outcome) with causative organism(s). For one patient in the Moxifloxacin group, the data is missing due to missing EOT visit (not displayed in the table below).</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin (Avelox, BAY12-8039)</title>
            <description>Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ertapenem</title>
            <description>Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Bacteriological Success at EOT Visit in the Per Protocol Population With Causative Organism(s)</title>
          <description>Bacteriological success = response classified as ‘eradication’ or ‘presumed eradication’ without occurrence of a superinfection. Bacteriological failure = response classified as ‘persistence’, ‘presumed persistence’, or ‘superinfection’.</description>
          <population>Per protocol population (subjects with no major protocol deviations that would have influenced the primary outcome) with causative organism(s). For one patient in the Moxifloxacin group, the data is missing due to missing EOT visit (not displayed in the table below).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Eradication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presumed Eradication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presumed Persistence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Superinfections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indeterminate/missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Calculated were 95% confidence intervals for the difference in success rates between treatment groups (moxifloxacin minus comparator).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size estimation was based on the primary efficacy variable.</non_inferiority_desc>
            <param_type>Difference in bact. success rates (in %)</param_type>
            <param_value>-3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.8</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>A positive value indicates an advantage for the treatment group of moxifloxacin, a negative value an advantage for the comparator group. Presumed eradications and eradications without superinfection were considered bacteriological successes.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Bacteriological Success at TOC Visit in the Per Protocol Population With Causative Organism(s)</title>
        <description>Bacteriological success = response classified as ‘eradication’ or ‘presumed eradication’ without occurrence of a superinfection. Bacteriological failure = response classified as ‘persistence’, ‘presumed persistence’, or ‘superinfection’ – additionally, any recurrence or reinfection was treated as bacteriological failure at TOC.</description>
        <time_frame>21 - 28 days after end of therapy</time_frame>
        <population>Per protocol population (subjects with no major protocol deviations that would have influenced the primary outcome) with causative organism(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin (Avelox, BAY12-8039)</title>
            <description>Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ertapenem</title>
            <description>Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Bacteriological Success at TOC Visit in the Per Protocol Population With Causative Organism(s)</title>
          <description>Bacteriological success = response classified as ‘eradication’ or ‘presumed eradication’ without occurrence of a superinfection. Bacteriological failure = response classified as ‘persistence’, ‘presumed persistence’, or ‘superinfection’ – additionally, any recurrence or reinfection was treated as bacteriological failure at TOC.</description>
          <population>Per protocol population (subjects with no major protocol deviations that would have influenced the primary outcome) with causative organism(s).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Eradication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presumed Eradication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presumed Persistence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Superinfections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reinfections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Calculated were 95% confidence intervals for the difference in success rates between treatment groups (moxifloxacin minus comparator).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size estimation was based on the primary efficacy variable.</non_inferiority_desc>
            <param_type>Difference in bact. success rates (in %)</param_type>
            <param_value>-3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.0</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>A positive value indicates an advantage for the treatment group of moxifloxacin, a negative value an advantage for the comparator group. Presumed eradications and eradications without super- or reinfection were considered bacteriological successes.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving Clinical Cure at TOC Visit in the Per Protocol Population With Causative Organism(s)</title>
        <description>Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC.</description>
        <time_frame>21 - 28 days after end of therapy</time_frame>
        <population>Per protocol population (subjects with no major protocol deviations that would have influenced the primary outcome) with causative organism(s).</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin (Avelox, BAY12-8039)</title>
            <description>Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ertapenem</title>
            <description>Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Clinical Cure at TOC Visit in the Per Protocol Population With Causative Organism(s)</title>
          <description>Clinical cure at TOC = resolution or improvement of clinical signs and symptoms related to the infection without the occurrence of a wound infection requiring a systemic antibiotic treatment. Clinical failure at TOC = either failure to respond or insufficient lessening of the signs and symptoms of infection at end of treatment (EOT) or reappearance of the signs and symptoms of the original infection from EOT up to TOC or wound infection requiring additional systemic antimicrobial therapy at any time up to TOC.</description>
          <population>Per protocol population (subjects with no major protocol deviations that would have influenced the primary outcome) with causative organism(s).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265"/>
                    <measurement group_id="O2" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Calculated were 95% confidence intervals for the difference in success rates between treatment groups (moxifloxacin minus comparator).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size estimation was based on the primary efficacy variable.</non_inferiority_desc>
            <param_type>Difference of cure rates (in percent)</param_type>
            <param_value>-2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.6</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
            <estimate_desc>A positive value indicates an advantage for the treatment group of moxifloxacin, a negative value an advantage for the comparator group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Died Due to Intra-abdominal Infections</title>
        <description>Number of subjects who had died due to intra abdominal infections by the time of TOC visit.</description>
        <time_frame>21 - 28 days after end of treatment at TOC Visit</time_frame>
        <population>Per protocol population comprising subjects with no major protocol deviations that would have influenced the primary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin (Avelox, BAY12-8039)</title>
            <description>Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ertapenem</title>
            <description>Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Died Due to Intra-abdominal Infections</title>
          <description>Number of subjects who had died due to intra abdominal infections by the time of TOC visit.</description>
          <population>Per protocol population comprising subjects with no major protocol deviations that would have influenced the primary outcome.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349"/>
                    <measurement group_id="O2" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Hospitalization</title>
        <description>Duration of hospitalization in the per protocol population.</description>
        <time_frame>From the first admission date to the discharge date (from 4 to 71 days after start of study medication)</time_frame>
        <population>Numbers refer to patients in the per protocol population with known end of hospitalization date.</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin (Avelox, BAY12-8039)</title>
            <description>Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ertapenem</title>
            <description>Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Hospitalization</title>
          <description>Duration of hospitalization in the per protocol population.</description>
          <population>Numbers refer to patients in the per protocol population with known end of hospitalization date.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="7.3"/>
                    <measurement group_id="O2" value="11.2" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Hospitalization Postoperatively</title>
        <description>Duration of hospitalization after the first surgery until discharge in the per protocol population.</description>
        <time_frame>Duration of hospitalization after the first surgery until discharge date (from 4 to 71 days after start of study medication)</time_frame>
        <population>Numbers refer to patients in the per protocol population with known end of hospitalization date.</population>
        <group_list>
          <group group_id="O1">
            <title>Moxifloxacin (Avelox, BAY12-8039)</title>
            <description>Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.</description>
          </group>
          <group group_id="O2">
            <title>Ertapenem</title>
            <description>Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Hospitalization Postoperatively</title>
          <description>Duration of hospitalization after the first surgery until discharge in the per protocol population.</description>
          <population>Numbers refer to patients in the per protocol population with known end of hospitalization date.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="346"/>
                <count group_id="O2" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="7.1"/>
                    <measurement group_id="O2" value="10.7" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Moxifloxacin (Avelox, BAY12-8039)</title>
          <description>Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.</description>
        </group>
        <group group_id="E2">
          <title>Ertapenem</title>
          <description>Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute mycardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="408"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Gastrointestinal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Intestinal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Jejunal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Unevaluable event</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Peritoneal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Retroperitoneal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Subdiaphragmatic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Failure to anastomose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Wound evisceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Postoperative respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Anastomotic complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Intestinal anastomosis complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Chest X-ray abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hairy cell leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Hydropneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="408"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="408"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="390"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="33" subjects_affected="30" subjects_at_risk="408"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="408"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="408"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="390"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The agreed point of publication is 12/18 months after database lock at the earliest. Bayer will have up to 30/45 days to review publications and may request an additional publication delay of up to 60 days to allow for filing a patent application (if applicable). No publication of single center data should be done prior of publication if multi-center data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

